Great Lakes 客製化 MARPE（微型螺釘輔助快速腭擴張器）可根據患者的獨特需求進行客製化調整。為達到預期的擴張效果，所需微型螺釘的數量與位置均由醫師指定。個性化的裝置設計與策略性的微型植體植入位置，有助於實現有效的治療。Great Lakes 技術嫻熟的技術人員將提供 […]
臨床見解與研究
睡眠不足會導致體重增加
People who shortened their sleep by around 80 minutes a night for six weeks gained weight—one pound on average—and were more sedentary, researchers at Columbia University Vagelos College of Physicians and Surgeons have found. “Our study shows that getting adequate sleep may help reduce the risk of weight gain and obesity-related […]
TAP Sleep Care 發表 myTAP 案例研究，顯示阻塞性睡眠呼吸中止症（OSA）症狀迅速改善
TAP Sleep Care® announced the publication of a compelling case report demonstrating the rapid, near-complete effectiveness of its myTAP® chairside titratable oral appliance when combined with a mouth shield for nasal breathing. Case #13 titled, “Two-Night Breakthrough in Treatment-Resistant OSA: Immediate-Effective Outcomes by combining Chairside OA with Mouth Shield,” authored […]
Apnimed 提交首次公開募股申請，其每日僅需服用一次的 OSA 藥丸即將獲得美國食品藥物管理局（FDA）的審核決定
Apnimed, the company behind what could become the first oral pharmacotherapy for obstructive sleep apnea (OSA), has filed for an initial public offering in the United States. The company is expected to list on Nasdaq under the ticker APMD. The filing comes at a notable moment for the biotech sector. [...]
Addex Research 強調調節 mGlu7 在控制睡眠與清醒方面的治療潛力
Addex Therapeutics announced publication of new preclinical research demonstrating that ADX71743, a selective negative allosteric modulator (NAM) of metabotropic glutamate receptor 7 (mGlu7), significantly modulates sleep-wake regulation and stress-related neurochemistry in animal models. The data, published in the International Journal of Neuropsychopharmacology, expands the growing body of evidence supporting mGlu7 […]
LivaNova 公布阻塞性睡眠呼吸中止症研究的 12 個月正面結果
近期發表的研究結果顯示，LivaNova Plc 的 aura6000 系統在治療中度至重度阻塞性睡眠呼吸中止症（OSA）方面具有療效。 這項發表於《內科學年鑑》（Annals of Internal Medicine）的研究，完整呈現了該公司 OSPREY 隨機對照試驗（RCT）為期 12 個月的結果，證實了近端舌下神經刺激（pHGNS）——一種差異化的神經刺激療法——的安全性與療效。 總體而言，研究作者結論指出，相較於[…]，針對 OSA 採用 pHGNS 可帶來具臨床意義的改善。
ŌURA 與 LillyDirect 將透過全新工具與節省方案，擴大對使用 GLP-1 療法患者的支援
ŌURA maker of the world’s most trusted smart ring, Oura Ring, and LillyDirect, Eli Lilly and Company’s digital health platform designed to connect people living with chronic conditions to the care, support, and prescribed medicines they need, today announced a collaboration enabling savings on the Oura Ring sizing kit. The […]
ProSomnus 與 MonitAir 攜手合作，以提升阻塞性睡眠呼吸中止症（OSA）的聯網照護服務
智慧睡眠醫學™（Smart Sleep Medicine™）的先驅 ProSomnus Sleep Technologies（以下簡稱「ProSomnus」），以及睡眠醫學領域首屈一指的數位健康與遠距監測平台 MonitAir, LLC（以下簡稱「MonitAir」），宣布展開合作，旨在為阻塞性睡眠呼吸中止症（OSA）患者提供連網、縱向追蹤及個人化的照護。透過此次合作，開立 ProSomnus RPMO₂ 處方的醫療服務提供者 […]
Jazz 於 SLEEP 2026 會議上發表大量數據，揭示 Xywav 對發作性睡病及特發性嗜睡症患者預後的實際影響
Jazz Pharmaceuticals plc delivered 11 late-breaking presentations at SLEEP 2026, including notable new research showcasing the comprehensive treatment outcomes of Xywav® (calcium, magnesium, potassium, and sodium oxybates) oral solution in patients with narcolepsy and idiopathic hypersomnia (IH). These late-breaking presentations advance scientific understanding of individualized dosing regimens and the broader cardiometabolic […]
最新研究：武田藥業的 Oveporexton 可改善第一型發作性睡病患者的日常功能、認知能力及夜間睡眠品質
New data presented by Takeda at SLEEP 2026 this week continues to build the case for oveporexton (TAK-861) as a potential disease-modifying treatment for narcolepsy type 1 (NT1). Oveporexton is designed to address the root cause of the disease, targeting the underlying orexin deficiency responsible for NT1. Results from two pivotal […]
